Good news: The pharma company NFlection Therapeutics is working on a new drug for the treatment of cutaneous neurofibromas (cNF). These days they achieved positive results in the phase 2b of testing for approval. This topical gel reduces the size of cNFs in the study. So there is a big hope, that this treatment will soon be available for patients with cutaneous neurofibromas that can occur in NF1 patients.
Find more info about the results from NFlection Therapeutics studies:
© 2024 NF Patients United